RxDoctor Payments Data

Robyn Glass

Optometrist · Eustis, FLNPI 1790236636

Payments from drug & device makers

$5,822in general payments, 2019–2025

Across 250 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alcon$998
  • Bausch & Lomb Americas Inc.$451
  • Biotissue Holdings Inc.$447
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$443
  • Novartis$439
  • plus $2K from 12 others

What the payments were for

  • Speaking & faculty fees$952%
  • Travel & lodging$64311%
  • Food & beverage$5,06787%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,822 in reported general payments places this provider in the 90th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$131,735
Medicare patients
537
Services billed
2,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine112$93,103
XdemvyLotilaner35$64,251
CequaCyclosporine37$27,233
XiidraLifitegrast19$15,606
LumiganBimatoprost21$5,159
Cyclosporine12$3,424
Latanoprost122$1,381
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat18$477
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha20$244
ErythromycinErythromycin Base13$128
Timolol Maleate11$103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$1,019$98,262133 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$404$64,25135 claims
Sun Pharmaceutical Industries Inc.Cequa$386$27,23337 claims
Bausch & Lomb Americas Inc.Xiidra$451$15,60619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Eustis

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →